Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced financial results for the third quarter ended on September...
-
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice...
-
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that three posters featuring new and previously reported...
-
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its...
-
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals”) today announced the pricing of its upsized initial public offering of 19,000,000 shares of its common stock...
-
Treatment with LB-102 resulted in a positive shift in disease severity as measured by mean change from baseline in Clinical Global Impression of Severity (CGI-S) scores Phase 3 clinical trial of...
-
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including...
-
Robust 359 patient trial met primary endpoint with statistically significant reduction in PANSS total score at all dose levels compared to placebo Clinically meaningful effect sizes were...
-
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including...
-
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including...